| SEC F | Form 4 |
|-------|--------|
|-------|--------|

П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burder hours per response: 0.5

| | | | | of Section So(n) of the investment Company Act of 1940 | | | | | | |
|--|---|----------------|----------|---|-------|---|-----------------------|--|--|--|
| | 1. Name and Addres Bowden Chris | 1 0 | Person* | 2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | |
| | Downen Chin | <u>stopner</u> | | 1 | | Director | 10% Owner | | | |
| | (1 oot) | (First) | (Middle) | [1 | X | Officer (give title below) | Other (specify below) | | | |
| | (Last) | · · / | () | 3. Date of Earliest Transaction (Month/Day/Year) | | Chief Medica | l Officer | | | |
| | C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET | | | 02/22/2019 | | | | | | |
| | | | | | | | | | | |
| | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | idual or Joint/Group Filir | ng (Check Applicable | | | |
| | (Street) | | | | Line) | | | | | |
| | CAMBRIDGE | МА | 02139 | | X | Form filed by One Re | porting Person | | | |
| | | | | | | Form filed by More the Person | an One Reporting | | | |
| | (City) | (State) | (Zip) | | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title | e of Security (Instr. 3) | Date Execution (Month/Day/Year) if any | | Execution Date, Transaction | | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership |
|----------|--------------------------|---|--|-----------------------------|---|--------|---|-------|--|---|---|
| | | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | (Instr. 4) |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of | | 6. Date Exerc Expiration Da (Month/Day/Y | ate | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|---|--|---|------------------------------|---|--------|-----|--|--------------------|---|--|---|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock option (right to buy) | \$58.86 | 02/22/2019 | | A | | 40,000 | | (1) | 02/22/2029 | Common stock | 40,000 | \$0.00 | 40,000 | D | |
| Restricted stock units | (2) | 02/22/2019 | | A | | 10,000 | | (3) | (3) | Common stock | 10,000 | \$0.00 | 10,000 | D | |

Explanation of Responses:

1. This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.

2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

3. The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.

/s/ William Cook as attorney-

02/26/2019

in-fact for Christopher Bowden ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.